Nancy S. Green

List of Publications by Year
in descending order

94 papers	3,569 citations	185998 28 h-index	138251 58 g-index
95 all docs	95 docs citations	95 times ranked	4209 citing authors

#	Article	IF	Citations
1	Managing Human Subjects Research During a Global Pandemic at an Academic Center: Lessons Learned From COVID-19. Academic Medicine, 2022, 97, 48-52.	0.8	4
2	Brain Magnetic Resonance Imaging and Angiography in Children with Sickle Cell Anaemia in Uganda in a Cross-Sectional Sample. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106343.	0.7	3
3	Transition Preparation and Satisfaction of Care Among Adolescents and Young Adults With Sickle Cell Disease at the Ghana Institute of Clinical Genetics. Journal of Pediatric Hematology/Oncology, 2021, Publish Ahead of Print, e682-e688.	0.3	0
4	Food insecurity, housing instability, and dietary quality among children with sickle cell disease: Assessment from a single urban center. Pediatric Blood and Cancer, 2021, , e29463.	0.8	2
5	Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research. Pediatric Blood and Cancer, 2020, 67, e28703.	0.8	22
6	Quality of Life of Latino and Non-Latino Youth With Sickle Cell Disease as Reported by Parents and Youth. Hispanic Health Care International, 2020, 18, 224-231.	0.5	9
7	Comparison of Hodgkinâ€™s Lymphoma in Children and Adolescents. A Twenty Year Experience with MHâ€™96 and LH2004 AIEOP (Italian Association of Pediatric Hematology and Oncology) Protocols. Cancers, 2020, 12, 1620.	1.7	10
8	Food Insecurity Is a Common Problem Affecting Dietary Quality in a Clinic-Based Pediatric Sickle Cell Disease Sample. Blood, 2020, 136, 8-9.	0.6	0
9	Mental Health Assessment of Youth with Sickle Cell Disease and Their Primary Caretakers: Baseline Depression and COVID-19 Pandemic-Associated Psychosocial Stress in a Multi-Site Study. Blood, 2020, 136, 41-42.	0.6	0
10	Burden of neurological and neurocognitive impairment in pediatric sickle cell anemia in Uganda (BRAIN SAFE): a cross-sectional study. BMC Pediatrics, 2019, 19, 381.	0.7	10
11	Greater number of perceived barriers to hydroxyurea associated with poorer healthâ€related quality of life in youth with sickle cell disease. Pediatric Blood and Cancer, 2019, 66, e27740.	0.8	11
12	HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol. BMC Pediatrics, 2019, 19, 354.	0.7	7
13	End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. Blood Advances, 2019, 3, 4002-4020.	2.5	21
14	Paediatric immunisation and chemoprophylaxis in a Ugandan sickle cell disease clinic. Journal of Paediatrics and Child Health, 2019, 55, 795-801.	0.4	3
15	HABIT, a Randomized Feasibility Trial to Increase Hydroxyurea Adherence, Suggests Improved Health-Related Quality of Life in Youths with Sickle Cell Disease. Journal of Pediatrics, 2018, 197, 177-185.e2.	0.9	13
16	Stroke Prevalence in Children With Sickle Cell Disease in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. Global Pediatric Health, 2018, 5, 2333794X1877497.	0.3	25
17	Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation. Genetics in Medicine, 2017, 19, 121-126.	1.1	73
18	Enhanced Long-Term Brain Magnetic Resonance Imaging Evaluation of Children with Sickle Cell Disease after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 670-676.	2.0	15

#	Article	IF	Citations
19	Optical Coherence Tomography Angiography and Ultra-widefield Fluorescein Angiography for Early Detection of Adolescent Sickle Retinopathy. American Journal of Ophthalmology, 2017, 183, 91-98.	1.7	43
20	Randomized feasibility trial to improve hydroxyurea adherence in youth ages 10â€“18 years through community health workers: The HABIT study. Pediatric Blood and Cancer, 2017, 64, e26689.	0.8	27
21	Assessment of Transition Readiness in Adolescents with Sickle Cell Disease and their Caretakers, A single institution experience. International Journal of Hematology Research, 2017, 3, 171-179.	0.2	6
22	Hydroxyurea Use in Young Children With Sickle Cell Anemia in New York State. American Journal of Preventive Medicine, 2016, 51, S31-S38.	1.6	29
23	Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease. Contemporary Clinical Trials, 2016, 49, 134-142.	0.8	7
24	Community Health Workers as Support for Sickle Cell Care. American Journal of Preventive Medicine, 2016, 51, S87-S98.	1.6	57
25	Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use. Pediatric Blood and Cancer, 2016, 63, 2146-2153.	0.8	25
26	Phenotypic Heterogeneity of Neutropenia and Gastrointestinal Illness Associated with G6PC3 Founder Mutation. Journal of Pediatric Hematology/Oncology, 2016, 38, e243-e247.	0.3	9
27	Evaluating Harms in the Assessment of Net Benefit: A Framework for Newborn Screening Condition Review. Maternal and Child Health Journal, 2016, 20, 693-700.	0.7	38
28	Family, Community, and Health System Considerations for Reducing the Burden of Pediatric Sickle Cell Disease in Uganda Through Newborn Screening. Global Pediatric Health, 2016, 3, 2333794X1663776.	0.3	18
29	Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. Journal of Clinical Pharmacology, 2016, 56, 298-306.	1.0	14
30	A framework for assessing outcomes from newborn screening: on the road to measuring its promise. Molecular Genetics and Metabolism, 2016, 118, 221-229.	0.5	19
31	Sickle cell in sickle cell disease in Latin America and the United States. Pediatric Blood and Cancer, 2015, 62, 1131-1136.	0.8	22
32	Variation in Gamma-Globin Expression before and after Induction with Hydroxyurea Associated with BCL11A, KLF1 and TAL1. PLoS ONE, 2015, 10, e0129431.	1.1	15
33	Mortality of New York children with sickle cell disease identified through newborn screening. Genetics in Medicine, 2015, 17, 452-459.	1.1	26
34	Hydroxyurea Improves Oxygen Saturation in Children With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2015, 37, 242-243.	0.3	14
35	Decision-making process for conditions nominated to the Recommended Uniform Screening Panel: statement of the US Department of Health and Human Services Secretaryâ€™s Advisory Committee on Heritable Disorders in Newborns and Children. Genetics in Medicine, 2014, 16, 183-187.	1.1	98
36	Do difficulties in swallowing medication impede the use of hydroxyurea in children?. Pediatric Blood and Cancer, 2014, 61, 1536-1539.	0.8	17

#	Article	IF	Citations
37	Pediatric Hematology Providers on Referral for Transplant Evaluation for Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2014, 36, 566-571.	0.3	9
38	Emerging science of hydroxyurea therapy for pediatric sickle cell disease. Pediatric Research, 2014, 75, 196-204.	1.1	50
39	A step forward back to (induced) fetal. Blood, 2014, 124, 993-995.	0.6	0
40	Sickle cell disease incidence among newborns in New York State by maternal race/ethnicity and nativity. Genetics in Medicine, 2013, 15, 222-228.	1.1	35
41	Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease. Pediatric Blood and Cancer, 2013, 60, 653-658.	0.8	60
42	Do Difficulties In Swallowing Medication Impede The Use Of Hydroxyurea In Children?. Blood, 2013, 122, 2967-2967.	0.6	1
43	Candidate Sequence Variants and Fetal Hemoglobin in Children with Sickle Cell Disease Treated with Hydroxyurea. PLoS ONE, 2013, 8, e55709.	1.1	26
44	A framework for key considerations regarding point-of-care screening of newborns. Genetics in Medicine, 2012, 14, 951-954.	1.1	8
45	Female factor IX deficiency due to maternally inherited Xâ€inactivation. Clinical Genetics, 2012, 82, 583-586.	1.0	6
46	Awareness of Sickle Cell among People of Reproductive Age: Dominicans and African Americans in Northern Manhattan. Journal of Urban Health, 2012, 89, 53-58.	1.8	16
47	Hematology Provider Perspectives On Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease. Blood, 2012, 120, 4276-4276.	0.6	0
48	Fetal Hemoglobin Levels in African American and Hispanic Children With Sickle Cell Disease at Baseline and in Response to Hydroxyurea. Journal of Pediatric Hematology/Oncology, 2011, 33, 496-499.	0.3	7
49	Weighing the Evidence for Newborn Screening for Hemoglobin H Disease. Journal of Pediatrics, 2011, 158, 780-783.	0.9	11
50	Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease. Pediatric Blood and Cancer, 2011, 56, 177-181.	0.8	37
51	Incomplete Follow-up of Hemoglobinopathy Carriers Identified by Newborn Screening Despite Reporting in Electronic Medical Records. Journal of the National Medical Association, 2011, 103, 852-862.	0.6	6
52	Effect of Hydroxyurea on Elevated Pulmonary Artery Pressures in Children with Sickle Cell Disease. Blood, 2011, 118, 4841-4841.	0.6	15
53	Systematic Evidence Review of Newborn Screening and Treatment of Severe Combined Immunodeficiency. Pediatrics, 2010, 125, e1226-e1235.	1.0	78
54	Committee report: Method for evaluating conditions nominated for population-based screening of newborns and children. Genetics in Medicine, 2010, 12, 153-159.	1.1	78

#	Article	IF	Citations
55	An evidence development process for newborn screening. Genetics in Medicine, 2010, 12, 131-134.	1.1	25
56	Weighing the evidence for newborn screening for early-infantile Krabbe disease. Genetics in Medicine, 2010, 12, 539-543.	1.1	58
57	Newborn Screening for Treatable Genetic Conditions: Past, Present and Future. Obstetrics and Gynecology Clinics of North America, 2010, 37, 11-21.	0.7	84
58	Genetics of HbF and HbF Response to Hydroxyurea In Pediatric Sickle Cell Disease: A Multi-Site Pilot Analysis of Candidate SNP Variants. Blood, 2010, 116, 2641-2641.	0.6	1
59	Understanding Provider Barriers to Hydroxyurea Use for Pediatric Sickle Cell Disease. Blood, 2010, 116, 255-255.	0.6	1
60	Increased Risk of Adverse Neurological Development for Late Preterm Infants. Journal of Pediatrics, 2009, 154, 169-176.e3.	0.9	364
61	Committee Report: Advancing the current recommended panel of conditions for newborn screening. Genetics in Medicine, 2007, 9, 792-796.	1.1	30
62	GREEN AND MURRAY RESPOND. American Journal of Public Health, 2007, 97, 589-590.	1.5	0
63	Cost of Hospitalization for Preterm and Low Birth Weight Infants in the United States. Pediatrics, 2007, 120, e1-e9.	1.0	458
64	Newborn Screening: Complexities in Universal Genetic Testing. American Journal of Public Health, 2006, 96, 1955-1959.	1.5	40
65	Ensuring the Safe and Effective Use of Medications During Pregnancy: Planning and Prevention Through Preconception Care. Maternal and Child Health Journal, 2006, 10, 129-135.	0.7	51
66	The long and short of it: telomeres and the brain. Lancet Neurology, The, 2006, 5, 999-1000.	4.9	4
67	Changes in the Gestational Age Distribution among U.S. Singleton Births: Impact on Rates of Late Preterm Birth, 1992 to 2002. Seminars in Perinatology, 2006, 30, 8-15.	1.1	464
68	Pilot programs in newborn screening. Mental Retardation and Developmental Disabilities Research Reviews, 2006, 12, 293-300.	3.5	19
69	Critical role of the March of Dimes in the expansion of newborn screening. Mental Retardation and Developmental Disabilities Research Reviews, 2006, 12, 280-287.	3.5	13
70	Research agenda for preterm birth: Recommendations from the March of Dimes. American Journal of Obstetrics and Gynecology, 2005, 193, 626-635.	0.7	184
71	Neonatal screening by DNA microarray: spots and chips. Nature Reviews Genetics, 2005, 6, 147-151.	7.7	62
72	Estimated Effect of 17 Alpha-Hydroxyprogesterone Caproate on Preterm Birth in the United States. Obstetrics and Gynecology, 2005, 105, 267-272.	1.2	124

#	Article	IF	Citations
73	Neonatal screening for inborn errors of metabolism. Lancet, The, 2005, 365, 2175-2176.	6.3	4
74	Attitudes about Genetics in Underserved, Culturally Diverse Populations. Public Health Genomics, 2005, 8, 161-172.	0.6	126
75	Implementation of Newborn Screening for Cystic Fibrosis Varies Widely Between States. Pediatrics, 2004, 114, 515-516.	1.0	4
76	Risks of Birth Defects and Other Adverse Outcomes Associated With Assisted Reproductive Technology. Pediatrics, 2004, 114, 256-259.	1.0	38
77	Newborn screening can readily become part of prenatal care. American Journal of Obstetrics and Gynecology, 2004, 191, 2180-2181.	0.7	1
78	Should preterm birth now be classified as a â€œcommon complex disorderâ€?. American Journal of Obstetrics and Gynecology, 2004, 191, S117.	0.7	2
79	Public perceptions about prematurity. American Journal of Preventive Medicine, 2003, 24, 120-127.	1.6	29
80	Recurrent Central Nervous System Acute Lymphoblastic Leukemia Associated with Cerebrospinal Fluid Eosinophilia and Basophilia: A Proposed Cytokine-Mediated Mechanism. Pediatric Hematology and Oncology, 2003, 20, 31-37.	0.3	4
81	Recurrent Central Nervous System Acute Lymphoblastic Leukemia Associated with Cerebrospinal Fluid Eosinophilia and Basophilia: A Proposed Cytokine-Mediated Mechanism. Pediatric Hematology and Oncology, 2003, 20, 31-37.	0.3	0
82	Congratulations! But Don't Forget to Evaluate. Pediatrics, 2002, 110, 848-848.	1.0	0
83	Human and murine immunoglobulin expression vector cassettes. Molecular Immunology, 2000, 37, 837-845.	1.0	54
84	Immunoglobulin hypermutation in cultured cells. Immunological Reviews, 1998, 162, 77-87.	2.8	14
85	Somatic hypermutation of antibody genes: a hot spot warms up. BioEssays, 1998, 20, 227-234.	1.2	18
86	The Promotion of â€‰V Region Hypermutation. Journal of Experimental Medicine, 1997, 185, 185-188.	4.2	16
87	Ig V region hypermutation in B cell hybrids mimics in vivo mutation and allows for isolation of clonal variants. Molecular Immunology, 1997, 34, 1095-1103.	1.0	3
88	A new method for estimating high mutation rates in cultured cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1996, 351, 105-116.	0.4	17
89	Senegal haplotype is associated with higher HbF than benin and cameroon haplotypes in African children with sickle cell anemia. American Journal of Hematology, 1993, 44, 145-146.	2.0	35
90	Yersinia Infections in Patients with Homozygous Beta-Thalassemia Associated with Iron Overload and its Treatment. Pediatric Hematology and Oncology, 1992, 9, 247-254.	0.3	45

#	Article	IF	Citations
91	Transient Erythroblastopenia of Childhood Presenting with Papilledema. Clinical Pediatrics, 1986, 25, 278-279.	0.4	13
92	Mental health assessment of youth with sickle cell disease and their primary caregivers during the COVIDâ€19 pandemic. Pediatric Blood and Cancer, 0, , .	0.8	1
93	Brentuximab vedotin in the treatment of paediatric patients with relapsed or refractory Hodgkin's lymphoma: Results of a realâ€life study. Pediatric Blood and Cancer, 0, , .	0.8	4
94	<scp>Antiâ€SARSâ€CoV</scp> â€19 antibodies in children and adults with sickle cell disease: A singleâ€site analysis in New York City. British Journal of Haematology, 0, , .	1.2	1